Neurocognitive performance and repeated-dose intravenous ketamine in major depressive disorder

2019 ◽  
Vol 246 ◽  
pp. 241-247 ◽  
Author(s):  
Wei Zheng ◽  
Yan-Ling Zhou ◽  
Wei-Jian Liu ◽  
Cheng-Yu Wang ◽  
Yan-Ni Zhan ◽  
...  
2021 ◽  
Vol 14 (10) ◽  
pp. e239587
Author(s):  
Siobhan Helen Gee ◽  
Camille Wratten ◽  
Ruth Cairns ◽  
Alastair Santhouse ◽  
David Taylor

Major depressive disorder (MDD) is common in general medical settings, and can usually be treated with conventional oral antidepressants. For some patients, however, oral treatment is refused or not possible, and the untreated symptoms can have a significant impact on the treatment of the acute medical problem. Use of intravenous ketamine has been widely reported in mental health settings for the treatment of MDD. We describe use of intravenous ketamine in a general medical hospital for the treatment of MDD in an 83-year-old male patient who refused food, fluid and medical investigations following a stroke.


2012 ◽  
Vol 46 (1) ◽  
pp. 117-123 ◽  
Author(s):  
Jordan R Covvey ◽  
Alexis Noble Crawford ◽  
Denise K Lowe

2018 ◽  
Vol 270 ◽  
pp. 211-218 ◽  
Author(s):  
Rachel G. Venezia ◽  
Marianne Gorlyn ◽  
Ainsley K. Burke ◽  
Maria A. Oquendo ◽  
J. John Mann ◽  
...  

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Alex Ferrer ◽  
Javier Labad ◽  
Neus Salvat-Pujol ◽  
Marta Barrachina ◽  
Javier Costas ◽  
...  

Abstract Brain-derived neurotrophic factor (BDNF) gene regulation has been linked to the pathophysiology of major depressive disorder (MDD). MDD patients show cognitive deficits, and altered BDNF regulation has a relevant role in neurocognitive functions. Our goal was to explore the association between BDNF genetic and epigenetic variations with neurocognitive performance in a group of MDD patients and healthy controls considering possible modulating factors. The sample included 134 subjects, 64 MDD patients, and 70 healthy controls. Clinical data, childhood maltreatment, and neurocognitive performance were assessed in all participants. Eleven single nucleotide polymorphisms (SNPs) and two promoter regions in the BDNF gene were selected for genotype and methylation analysis. The role of interactions between BDNF genetic and epigenetic variations with MDD diagnosis, sex, and Childhood Trauma Questionnaire (CTQ) scores was also explored. We observed significant associations between neurocognitive performance and two BDNF SNPs (rs908867 and rs925946), an effect that was significantly mediated by methylation values at specific promoter I sites. We identified significant associations between neurocognitive results and methylation status as well as its interactions with MDD diagnosis, sex, and CTQ scores. Our results support the hypothesis that BDNF gene SNPs and methylation status, as well as their interactions with modulating factors, can influence cognition. Further studies are required to confirm the effect of BDNF variations and cognitive function in larger samples.


Sign in / Sign up

Export Citation Format

Share Document